IN8bio, Inc. (INAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
INAB Stock Price Chart Interactive Chart >
INAB Price/Volume Stats
| Current price | $2.28 | 52-week high | $4.98 |
| Prev. close | $2.07 | 52-week low | $1.38 |
| Day low | $2.05 | Volume | 59,400 |
| Day high | $2.36 | Avg. volume | 44,994 |
| 50-day MA | $2.06 | Dividend yield | N/A |
| 200-day MA | $2.27 | Market Cap | 55.86M |
IN8bio, Inc. (INAB) Company Bio
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Latest INAB News From Around the Web
Below are the latest news stories about IN8BIO INC that investors may wish to consider to help them evaluate INAB as an investment opportunity.
IN8bio to Present at the B. Riley Securities’ 3rd Annual Virtual Oncology ConferenceNEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a company overview at the B. Riley Securities’ 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 12:00pm ET. Interested parties can register for the webcast using the B. Riley Securities conference website: https://brileyoncology22.sequiree |
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline GoalsAll three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial data from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastoma multiforme (GBM). Company-sponsored Phase 2 multi-center clinical trial of autologous INB-400 gamma-delta T cells in newly diagnosed GBM patients to start enrollment by Q3 2023. Submission of Investigational New Drug Appli |
IN8bio to Present at Biotech Showcase 2023 in San FranciscoCompany to be in San Francisco January 9-11, 2023, during the 41st Annual J.P. Morgan Healthcare Conference NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present at Biotech Showcase 2023 on Monday, January 9, 2023, and will also participate in a panel on Tuesday, January 10, 2023, at the Hilton San Francisco |
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100Results from the first cohort of patients with hematological malignancies show patients remained progression free; ongoing durations of response extend beyond 2.5 years (31.9 months)INB-100 continues to demonstrate a manageable safety profile with no dose-limiting toxicities (DLTs) observed to dateEnrollment for Cohort 2 has been initiated with additional clinical updates expected in 2Q 2023Company to host conference call to discuss data and recent clinical updates at 8:30 a.m. ET today NEW YORK |
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for GlioblastomaNEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of a genetically modified autologous gamma-delta T cell therapy (INB-400) targeting newly diagnosed glioblastoma (GBM). The study will assess the safety, efficacy and tolerability of genetically modified DeltEx drug-resistant immunotherapy (DRI) cells at leading medical centers across the United States. |
INAB Price Returns
| 1-mo | 9.09% |
| 3-mo | 23.24% |
| 6-mo | -4.20% |
| 1-year | -24.00% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -1.30% |
| 2022 | -47.38% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...